Page 3 - Garrye Menzel News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Adaptimmune Therapeutics (NASDAQ:ADAP) PT Lowered to $1 00 at Barclays

Adaptimmune Therapeutics (NASDAQ:ADAP) PT Lowered to $1 00 at Barclays
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited kingdom generalUnited statesGarrye menzelEf hutton acquisition coCitigroup incNorthern trust corpBlackrock incRenaissance technologiesArtal groupAdaptimmune therapeuticsFree reportGet free reportDirector garryTrust corpAdaptimmune therapeutics daily

Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $0 82

Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Gap Up to $0 82
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited kingdom generalUnited statesGarrye menzelRenaissance technologiesEf hutton acquisition coBlackrock incGoldman sachs group incSecurities exchange commissionAcadian asset managementAdaptimmune therapeuticsGet free reportDirector garryExchange commissionAsset managementStreet corp

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Given Consensus Rating of Moderate Buy by Brokerages

Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) has received an average recommendation of “Moderate Buy” from the five analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among analysts […]

United kingdomUnited statesGarrye menzelEf hutton acquisition coLong focus capital managementSecurities exchange commissionBaillie gifford coHarbor capital advisors incJpmorgan chase coAdaptimmune therapeutics company profileAdaptimmune therapeuticsGet free reportDirector garryExchange commissionCapital advisorsFocus capital management

Adaptimmune Therapeutics (ADAP) Scheduled to Post Quarterly Earnings on Wednesday

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) is scheduled to be announcing its earnings results on Wednesday, August 2nd. Adaptimmune Therapeutics (NASDAQ:ADAP – Get Free Report) last announced its quarterly earnings results on Friday, May 12th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by […]

United kingdomUnited statesGarrye menzelAdaptimmune therapeutics company profileVirtu financialArrowstreet capital limited partnershipEf hutton acquisition coAdaptimmune therapeuticsGet free reportDirector garrySigma investmentsCapital limited partnershipJane street groupAdaptimmune therapeutics dailyNasdaq adap

Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Price Up 6 7%

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report) rose 6.7% on Monday . The company traded as high as $0.95 and last traded at $0.95. Approximately 230,424 shares were traded during trading, a decline of 69% from the average daily volume of 747,531 shares. The stock had previously closed at $0.89. Analyst Upgrades […]

United statesUnited kingdomGarrye menzelEf hutton acquisition coArrowstreet capital limited partnershipSecurities exchange commissionVirtu financialSusquehanna international groupAdaptimmune therapeuticsGet free reportDirector garryExchange commissionSigma investmentsInternational groupAdaptimmune therapeutics dailyNasdaq adap